AFCG Q2: Net Investment Income Rises, But Justice Cannabis Default Looms
AFCG sits 37% above its 52-week low of $2.06.
Summary
AFCG reported Q2 net investment income of $3.48M, but its largest loan to Justice Cannabis matured unpaid, leaving $78.8M in litigation. Nonaccruals remain high at 22.7% of fair value.
Key Events · Earnings and Guidance · AFCG
-
Justice Cannabis Loan Defaults at Maturity
The $78.8M credit facility to Justice Cannabis Company matured May 1, 2026 without repayment. AFCG is pursuing litigation and has noticed collateral dispositions for September 24 and October 6, 2026.
-
Nonaccrual Investments Remain Elevated
Three portfolio companies are on nonaccrual status, representing 22.7% of total debt investments at fair value ($65.9M fair value vs $126.5M amortized cost).
-
Q2 Net Investment Income Positive
Net investment income was $3.48M for Q2 2026, up from a net loss of $13.16M in Q2 2025, driven by higher interest income and lower credit loss provisions.
-
Leverage Increased Temporarily
Revolving credit facility was temporarily increased to $110M and fully drawn at quarter end. On July 1, 2026, the company repaid $84.4M on the revolver and $20M on the TCGSL facility.
Analysis · AFCG · Unknown
Advanced Flower Capital swung to positive net investment income of $3.48M in Q2 2026, but the quarter is overshadowed by the maturity of its largest loan — Justice Cannabis Company — without repayment. The $78.8M exposure, now in active litigation, represents a substantial portion of the company's $187M net assets. Nonaccrual investments remain elevated at 22.7% of fair value, and the company is pursuing collateral dispositions scheduled for September and October 2026. The company also drew down its full $110M revolving credit facility, though it repaid $84.4M on July 1, 2026. The new $5M buyback program and insider accumulation provide some support, but the credit risk is the dominant story.
At the time of this filing, AFCG was trading at $2.82 on NASDAQ in the Unknown sector, with a market capitalization of approximately $64.3M. The 52-week trading range was $2.06 to $5.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.